Form 4: Phio Pharmaceuticals Director Acquires Additional Shares

Robert L. Ferrara, a director of Phio Pharmaceuticals Corp., purchased 2,500 shares of common stock at a weighted average price of $1.82 on May 20, 2025.

Summary

• On May 20, 2025, Robert L. Ferrara, a director at Phio Pharmaceuticals Corp., acquired 2,500 shares of the company's common stock.
• The shares were purchased at a weighted average price of $1.82 per share.
• Following the transaction, Ferrara directly owns 13,166 shares, which includes shares underlying unvested restricted stock units.
• The reported securities have been adjusted to reflect prior reverse stock splits.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but the small transaction size limits the impact.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, buys or sells shares of their company's stock. It provides transparency to the market regarding the transactions of company insiders.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholders as it signals confidence from a company director.

Key Dates

Keywords

Phio Pharmaceuticals, Director, Stock Purchase, Form 4, Ferrara, Beneficial Ownership